Three weekly high-dose chemotherapy regimens in combination with weekly cetuximab are
the treatment of choice for patients with recurrent/metastatic (R/M) head and neck squamous …

For patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma
(SCCHN) limited therapeutic options exist. Only a subset of patients is suitable for …

Abstract Lessons Learned Chemotherapy for recurrent, metastatic squamous cell carcinoma
of the head and neck need not be known for extreme toxicity. The weekly regimen studied …

Background The effectiveness of the combination chemotherapy of weekly paclitaxel and
cetuximab has not yet been compared to that of the current standard regimen, EXTREME …

Objective For most patients suffering from recurrent and/or metastatic head and neck
squamous cell carcinoma (R/M HNSCC), chemotherapy is the main option after considering …

BACKGROUND The targeted therapy cetuximab [directed at the epidermal growth factor
receptor (EGFR)] in combination with 5-fluorouracil and platinum-based chemotherapy (the …

Background Cetuximab in combination with platinum and 5-fluorouracil is the standard of
care in the first-line treatment of patients with recurrent/metastatic head and neck squamous …

5567 Background: Cetuximab in combination with platinum and 5FU has become a
standard in first-line treatment of patients (pts) with R/M SCCHN. Cetuximab and taxane …

5505 Background: Cetuximab in combination with platinum and 5FU (PFEx) has become a
standard in first-line treatment of patients (pts) with R/M SCCHN. Cetuximab and taxane …

BACKGROUND: This study was undertaken to report the results of weekly combination
chemotherapy with cetuximab in recurrent/metastatic head and neck squamous cell …